Edition:
United States

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

11.03USD
1:44pm EDT
Change (% chg)

$0.32 (+2.99%)
Prev Close
$10.71
Open
$11.15
Day's High
$11.19
Day's Low
$10.81
Volume
32,313
Avg. Vol
12,626
52-wk High
$11.19
52-wk Low
$5.70

Chart for

About

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $142.67
Shares Outstanding(Mil.): 13.32
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Oramed pharmaceuticals ‍concludes its meeting with U.S. FDA regarding its oral insulin formulation​

* ‍Concluded its meeting with U.S. FDA regarding ORMD-0801, company's novel oral insulin formulation​

Sep 05 2017

BRIEF-Oramed Pharmaceuticals Inc's CFO Yifat Zommer resigned from her positions with co per personal reasons

* Oramed Pharmaceuticals Inc - on July 18, yifat zommer, cfo of co resigned from her positions with co per personal reasons, effective August 1, 2017

Jul 21 2017

BRIEF-Oramed announces dual-listing on Tel Aviv stock exchange

* Oramed Pharmaceuticals Inc - ‍Based on current market capitalization of company, it is expected that Oramed will be included in TA SME-60 index​

Jul 05 2017

BRIEF-Oramed granted Japanese patent for combination insulin and glp-1 analog capsule

* Oramed granted Japanese patent for combination insulin and glp-1 analog capsule

Jun 27 2017

BRIEF-Oramed receives Israel regulatory approval

* Oramed receives Israel regulatory approval to conduct human study for new oral leptin capsule

May 02 2017

Earnings vs. Estimates